PD5-2-6: Hypofractionated stereotactic body radiotherapy in patients with peripherally or centrally located medically inoperable stage I or isolated recurrent non-small cell lung cancer  by Chang, Joe Y. et al.
Copyright © 2007 by the International Association for the Study of Lung Cancer S477
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
patients who receive similar local therapy of primary disease (median 
survival 12 vs. 8 months).
Conclusions: For NSCLC patients with brain as a solitary organ site of 
metastasis and a single brain metastasis, radiotherapy or resection for 
primary lung disease markedly improves median survival. For those 
with extracranial solitary organ sites of metastases, local therapy of pri-
mary thoracic disease improves survival, but this beneﬁt is lost in those 
who survive beyond one year. Patients with extracranial metastases 
rarely received local therapy for metastases, whereas brain metastasis 
patients invariably do. Our results suggest a potential beneﬁt and need 
for a prospective study of surgical resection or radiotherapy to all vis-
ible disease in patients with oligometastatic NSCLC. 
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Background: To evaluate the therapeutic efﬁcacy and treatment-
related toxicity of image-guided hypofractionated stereotactic body 
radiotherapy (SBRT) in patients with peripherally or centrally located, 
medically inoperable stage I or isolated recurrent NSCLC. 
Methods: Subjects had pathologically conﬁrmed stage I (n=49) or 
isolated recurrent (n=24) NSCLC. Among 73 patients, 25 patients had 
centrally located lesions deﬁned as within 2 cm of bronchial tree, major 
vessels, esophagus, heart and other mediastinal structures but no direct 
invasion. Internal gross target volume was delineated using maximal 
intensity projection created by combining the data from a 4-D CT da-
taset at different respiratory phases. The clinical target volume was the 
internal gross target volume plus an 8-mm margin, and a 3-mm setup 
uncertainty margin was added to determine the planning target volume. 
For each fraction the patient was aligned using in-room CT-on-rails. 
The prescribed dose was 50 Gy to PTV at daily 12.5 Gy/fraction for 4 
contiguous days. Dose constraint of major mediastinal critical organs 
was 40 Gy less than 10 cc except for esophagus in which 40 Gy was 
limited to less than 1 cc. 
Results: Median follow-up was 18 months (3-28 months). The overall 
progression-free survival rate at the treated site was 95.9%. For stage I 
disease, the complete response (CR), partial response (PR) and stable 
disease (SD) rate were 33%, 35% and 31% respectively. There was no 
signiﬁcant difference in response rate between stage Ia (n=42) and Ib 
(n=7). Two patients (4.1%) developed mediastinal lymph node metasta-
sis. For isolated recurrent disease, the CR, PR and SD rate were 45.8%, 
33.3%, and 12.5% respectively. Mediastinal lymph node metastasis 
happened in three patients (12.5%). There was 6.1% grade II but no 
grade III and above radiation pneumonitis in stage I disease. Three 
patients with recurrent disease had worse dyspnea after SBRT and 
one patients needed nasonal oxygenation. No esophagitis was noted. 
22.8% of patients developed grade II dermatitis at the treated site that 
appears related to the dose (>35 Gy) and volume of the skin treated. 
Three patient developed chronic skin scar and ﬁve patients had chronic 
mild neurogenic chest pain due to intercostal nerve injury. There was 
no increased toxicity noted in centrally located lesions compared with 
peripherally located lesions.
Conclusions: Image-guided SBRT using 50 Gy in four fractions 
achieved excellent local progression-free survival rate with minimal 
toxicity in peripherally or centrally located stage I or isolated recurrent 
NSCLC. Long-term follow up and further studies are needed to evalu-
ate the toxicity of centrally located lesions and higher dose volume 
constraints to critical structures. 
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Background: Radiotherapy is the cornerstone treatment for unresect-
able LA-NSCLC. Outcomes with standard RT scheduling in this patient 
subgroup are poor and new approaches like altered fractionation were 
studied. Even though many trials investigated the value of these new 
strategies, their results were inconsistent. We performed a meta-analy-
sis of those trials to try to clarify this matter.
Methods: We performed a thorough literature search to identify phase 
III randomized trials where standard RT was compared with an altered 
RT fractionation in the treatment of LA-NSCLC. The trials were 
analysed for any relevant end point and a meta-analysis of the selected 
trials was performed.
Results: We found 6 trials with n=1484 (n=793 for HFRT and n=691 
for SRT). An absolute improvement in mortality rate of 4.2% with 
HFRT was shown: 90.7% for SRT vs 86.5% for HFRT (p<0.02), with 
a HR=0.65 (CI 95%: 0.47-0.90). Results persist even excluding RTOG 
8808 and CHART. Two year survival was also improved (31.8 vs 
26.1%). Response rate (data available from 2 studies) were similar: 
60.8 vs. 52.5%; HFRT was associated with a reduction of 28% in local 
failures (HR: 0.72, CI: 0.56-0.93). Toxicity: HFRT produced a signiﬁ-
cantly increased incidence of Grade 3 and 4 esophagitis (18.1 vs. 8.7%, 
p<0.001); but grade 3/4 pneumonitis was less frequent with HFRT (8.2 
vs. 11.6%, p<0.02). 
